120 related articles for article (PubMed ID: 37401252)
21. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
Carter TC; Medina-Flores R; Lawler BE
Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
[TBL] [Abstract][Full Text] [Related]
23. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
24. Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma.
Liu Y; Strawderman MS; Warren KT; Richardson M; Serventi JN; Mohile NA; Milano MT; Walter KA
Anticancer Res; 2020 Oct; 40(10):5801-5806. PubMed ID: 32988908
[TBL] [Abstract][Full Text] [Related]
25. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
26. A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).
Arakawa Y; Sasaki K; Mineharu Y; Uto M; Mizowaki T; Mizusawa J; Sekino Y; Ono T; Aoyama H; Satomi K; Ichimura K; Kinoshita M; Ohno M; Ito Y; Nishikawa R; Fukuda H; Nishimura Y; Narita Y;
BMC Cancer; 2021 Oct; 21(1):1105. PubMed ID: 34654402
[TBL] [Abstract][Full Text] [Related]
27. Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients.
Behm T; Horowski A; Schneider S; Bock HC; Mielke D; Rohde V; Stockhammer F
Clin Neurol Neurosurg; 2013 Oct; 115(10):2142-6. PubMed ID: 23993314
[TBL] [Abstract][Full Text] [Related]
28. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma.
Omar AI
J Vis Exp; 2014 Oct; (92):e51638. PubMed ID: 25407354
[TBL] [Abstract][Full Text] [Related]
29. Short-term radiotherapy followed by adjuvant chemotherapy in poor-prognosis patients with glioblastoma.
Muni R; Minniti G; Lanzetta G; Caporello P; Frati A; Enrici MM; Marchetti P; Enrici RM
Tumori; 2010; 96(1):60-4. PubMed ID: 20437859
[TBL] [Abstract][Full Text] [Related]
30. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
31. Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis.
Rusthoven CG; Koshy M; Sher DJ; Ney DE; Gaspar LE; Jones BL; Karam SD; Amini A; Ormond DR; Youssef AS; Kavanagh BD
JAMA Neurol; 2016 Jul; 73(7):821-8. PubMed ID: 27214765
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant Temozolomide for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies.
Zhao Y; Wu J; Shi L
Clin Neuropharmacol; 2021 Jul-Aug 01; 44(4):132-137. PubMed ID: 34039842
[TBL] [Abstract][Full Text] [Related]
33. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Hata N; Mizoguchi M; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Amemiya T; Michiwaki Y; Fujioka Y; Takigawa K; Suzuki SO; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iihara K
J Neurooncol; 2020 Feb; 146(3):451-458. PubMed ID: 32020475
[TBL] [Abstract][Full Text] [Related]
34. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
[TBL] [Abstract][Full Text] [Related]
35. A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Gilbert MR; Dignam JJ; Armstrong TS; Wefel JS; Blumenthal DT; Vogelbaum MA; Colman H; Chakravarti A; Pugh S; Won M; Jeraj R; Brown PD; Jaeckle KA; Schiff D; Stieber VW; Brachman DG; Werner-Wasik M; Tremont-Lukats IW; Sulman EP; Aldape KD; Curran WJ; Mehta MP
N Engl J Med; 2014 Feb; 370(8):699-708. PubMed ID: 24552317
[TBL] [Abstract][Full Text] [Related]
36. Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Jablonska PA; Diez-Valle R; Pérez-Larraya JG; Moreno-Jiménez M; Idoate MÁ; Arbea L; Tejada S; Garcia de Eulate MR; Ramos L; Arbizu J; Domínguez P; Aristu JJ
PLoS One; 2019; 14(6):e0217881. PubMed ID: 31170245
[TBL] [Abstract][Full Text] [Related]
37. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
38. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.
Minniti G; De Sanctis V; Muni R; Filippone F; Bozzao A; Valeriani M; Osti MF; De Paula U; Lanzetta G; Tombolini V; Maurizi Enrici R
J Neurooncol; 2008 May; 88(1):97-103. PubMed ID: 18250965
[TBL] [Abstract][Full Text] [Related]
39. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917
[TBL] [Abstract][Full Text] [Related]
40. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Baumert BG; Hegi ME; van den Bent MJ; von Deimling A; Gorlia T; Hoang-Xuan K; Brandes AA; Kantor G; Taphoorn MJB; Hassel MB; Hartmann C; Ryan G; Capper D; Kros JM; Kurscheid S; Wick W; Enting R; Reni M; Thiessen B; Dhermain F; Bromberg JE; Feuvret L; Reijneveld JC; Chinot O; Gijtenbeek JMM; Rossiter JP; Dif N; Balana C; Bravo-Marques J; Clement PM; Marosi C; Tzuk-Shina T; Nordal RA; Rees J; Lacombe D; Mason WP; Stupp R
Lancet Oncol; 2016 Nov; 17(11):1521-1532. PubMed ID: 27686946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
